Shots:
The first patient has been dosed in the P-II study to evaluate the safety & efficacy of SP-103 in 80 patients with acute LBP. The study is expected to complete in 1yr. & was based on the favorable data from the PK study
SP-103 has the same adhesion characteristics as cilex’s marketed product ZTlido which includes label claims & enhanced adhesive qualities over competing products.
Scilex’s triple-strength SP-103 is a non-aqueous lidocaine topical system that undergoes clinical development in acute LBP. Under the SPAC with Vickers, the combined company will be renamed Scilex & its common stock will be listed on Nasdaq with the ticker symbols “SCLX” & “SCLXW” & the transaction is expected to close in Q3’22
Ref: Globenewswire | Image: Scilex
